Litigation Details for UCB, Inc. v. Apotex Inc. (S.D. Fla. 2018)

UCB, Inc. v. Apotex Inc. (S.D. Fla. 2018)

Docket		Date Filed	2018-04-17
Court	District Court, S.D. Florida	Date Terminated	2019-04-01
Cause	35:0271 Patent Infringement	Assigned To	Marcia G. Cooke
Jury Demand	None	Referred To	Patrick M. Hunt
Parties	UCB, INC.
Patents	8,633,194
Attorneys	Robert E. Counihan
Firms	White & Case, LLP*
Link to Docket	External link to docket

Details for UCB, Inc. v. Apotex Inc. (S.D. Fla. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-17				External link to document

UCB v. Apotex (0:18-cv-60846) Litigation Summary and Patent/Exclusivity Analysis

Last updated: July 16, 2026

UCB, Inc. v. Apotex Inc., case number 0:18-cv-60846, is a US patent infringement dispute in which UCB asserted rights against Apotex in a Paragraph IV generics context. The docket indicates an active district-court litigation track with briefing and case-management activity typical of Hatch-Waxman disputes. Without the underlying filings, asserted patents, claim charts, or settlement/consent judgment documents on the record provided here, a complete, accurate patent-by-patent infringement, validity, and exclusivity analysis cannot be produced.

Because the request is limited to a litigation summary and analysis for that specific case, and no docket content (complaint, answer, claim list, ANDA number, Orange Book patents, infringement allegations, or final dispositions) is included, producing an exact case outcome, asserted patent estate, or timing impact would require details that are not present.

What is the litigation posture in UCB, Inc. v. Apotex Inc. 0:18-cv-60846?

Answer: The case is filed in US district court under 0:18-cv-60846 and proceeds under a patent infringement framework consistent with Hatch-Waxman Paragraph IV litigation, but the specific posture milestones (TRO, preliminary injunction, Markman schedule, dispositive motions, claim construction outcomes, trial dates, final judgment) are not available from the provided information.

Key procedural elements that typically define this docket

• Complaint filed by UCB alleging infringement of one or more Orange Book-listed patents tied to a branded reference product.
• Apotex response via answer and defenses (non-infringement, invalidity, unenforceability, statutory limitations).
• Claim construction (Markman) and/or expert discovery.
• Dispositive motion phase (summary judgment on infringement/validity) and settlement possibility.

Which patents were asserted in UCB v. Apotex 0:18-cv-60846, and what is the infringement theory?

Answer: The asserted patent numbers, application/patent family, specific claim scope, and infringement theory (product-by-process, formulation, method-of-use, or dosing regimen) are not identified in the information provided.

What an accurate asserted-patent map requires

• List of asserted US patents in the complaint.
• Orange Book “patent list” associated with the relevant NDA/BLA.
• Apotex’s ANDA filing date, Paragraph IV certifications (certification numbers and listed patents).
• UCB’s theory of infringement for each asserted claim.

What defenses did Apotex raise in 0:18-cv-60846 (invalidity, non-infringement, inequitable conduct)?

Answer: The specific defenses asserted by Apotex (invalidity grounds such as anticipation/obviousness, claim indefiniteness, written description/enablement, or inequitable conduct) are not available from the provided record.

Common Hatch-Waxman defense patterns

• Non-infringement via differences in ANDA formulation/composition, manufacturing method, or proposed labels.
• Invalidity over prior art references, obviousness combinations, and §112 challenges.
• Statutory bars and patent-enforceability challenges.

Did UCB win, lose, or settle UCB v. Apotex 0:18-cv-60846?

Answer: The case disposition (final judgment, dismissal, consent judgment, or settlement terms) is not stated in the information provided, so the outcome cannot be accurately summarized.

How to interpret settlement vs. final judgment in this docket class

• Settlement commonly results in a consent judgment or a stipulation of dismissal with a settlement date and exclusivity-based trigger date for generic launch.
• Final judgment includes court findings on infringement/validity and can shift the expected market entry date based on which claims survive appeal.

When does exclusivity end for the underlying branded product, and how does the case affect launch timing?

Answer: The underlying branded product and its exclusivity framework (NCE/505(b)(2) or 3-year/5-year exclusivity, patent term protections, pediatric extensions, and method/formulation-specific barriers) are not identified in the information provided, so the exclusivity timeline cannot be calculated.

Inputs needed to compute a launch timeline from this case

• Brand reference product identity (NDA/BLA number).
• Orange Book exclusivity and the patent-term calendar for each listed patent.
• Whether UCB asserted formulation and/or method-of-use claims, which can extend barriers beyond composition-of-matter.
• Any settlement-driven agreed launch dates.

What is the Orange Book status tied to UCB’s asserted patents in 0:18-cv-60846?

Answer: The Orange Book listing status (listed vs. delisted, expiration dates, exclusivity codes, or patent-by-patent remaining lives) is not available from the provided information.

What a correct Orange Book status table would include

• NDA/BLA number
• Patent numbers listed for the NDA
• Patent expiration and any PTA/PTE
• Exclusivity type and end date
• Apotex certification status per patent

How strong is UCB’s patent estate in this litigation (validity and enforceability signals)?

Answer: A strength assessment depends on the asserted patents’ prosecution history, citation profile, claim construction record, and dispositive-motion outcomes. None of that case-specific content is provided.

Typical strength indicators

• Recent claim amendments and narrowing during prosecution.
• Prior art landscape and whether the same patents have been litigated previously.
• Court rulings on claim construction or dispositive validity/infringement.

How does the litigation compare with other UCB vs. generic challenges in the same drug class?

Answer: No comparator dataset (other UCB v. generic cases by ANDA holder) and no underlying drug identity is available, so a meaningful comparison cannot be made.

What generic entry risks exist for Apotex if the case does not fully bar launch?

Answer: Generic launch risk depends on (1) which patents are still enforceable after the case outcome, (2) whether Apotex can design around asserted claims, and (3) whether any remaining patents are not asserted in this matter. Those specifics are not provided.

Typical “remaining-barrier” scenarios

• Settlement allows launch but preserves other unasserted patents for later litigation.
• Narrow validity findings eliminate some claims but leave others in force, constraining design-around.

What are the commercial and licensing implications of 0:18-cv-60846 for UCB and Apotex?

Answer: Commercial impact requires (a) the product’s revenue exposure in the relevant geography and (b) settlement terms or court outcomes that define market-entry dates. The underlying drug and any terms are not provided.

Commercial decision points driven by these dockets

• Expected generic launch date vs. remaining branded revenue window.
• Scope of settlement: single NDA vs. portfolio, single dosage form vs. multiple SKUs.
• Potential licensing or cross-licenses between brand and generic firms.

Timeline (template) for UCB v. Apotex 0:18-cv-60846

Answer: A case timeline cannot be populated without docket events and dates (filing date, service date, scheduling order, Markman date, motion deadlines, and disposition).

Event type	What to extract from docket	Status
Complaint filed	Filing date, asserted patents	Not provided
Answer filed	Defenses and counterclaims	Not provided
Markman/claim construction	Order date, briefs, rulings	Not provided
Dispositive motions	Summary judgment dates/denials/grants	Not provided
Settlement/case resolution	Consent judgment, dismissal, launch dates	Not provided

Key Takeaways

• UCB, Inc. v. Apotex Inc., 0:18-cv-60846 is an active district-court patent litigation matter consistent with Hatch-Waxman-style generic challenges, but the requested “litigation summary and analysis” cannot be completed accurately because asserted patents, claims, defenses, and disposition are not included in the information provided.
• A patent estate and exclusivity impact analysis requires the underlying Orange Book/NDA link and the docket’s substantive filings or final judgment/settlement documents, which are not present here.

FAQs

1. What does “0:18-cv-60846” indicate about the case track and jurisdiction?
2. How do I determine which patents were listed in the Orange Book for the reference product behind UCB v. Apotex?
3. What dispositive motion outcomes most influence Hatch-Waxman launch timing in district court?
4. How do settlement agreements typically structure generic launch dates in brand vs. Paragraph IV cases?
5. What factors drive design-around feasibility when asserted claims are formulation or method-of-use?

References

1. Court docket entry for UCB, Inc. v. Apotex Inc., case number 0:18-cv-60846 (source not provided in the prompt).